Related Experiment Video
Updated: Aug 19, 2026

Measuring Rates of Herbicide Metabolism in Dicot Weeds with an Excised Leaf Assay
Published on: September 7, 2015
A review of epidemiologic studies of triazine herbicides and cancer
1Department of Epidemiology, School of Public Health, University of Alabama at Birmingham 35294-0008, USA.
Abstract:
We evaluated epidemiologic evidence pertaining to the human carcinogenic potential of triazine herbicides in general and of atrazine, the most common triazine. Cancers for which data are available included non-Hodgkin's lymphoma, Hodgkin's disease, leukemia, multiple myeloma, soft tissue sarcoma, colon cancer, and ovarian cancer. The investigations had methodologic limitations, including lack of in-depth exposure measurements and small numbers of subjects with heavy exposure and/or with many years since starting exposure, possibly required for the induction of cancer. The relation between triazines and non-Hodgkin's lymphoma has been assessed in four independent population-based case-control studies, reporting odds ratios ranging from 1.2 to 2.5. However, chance and/or confounding by other agricultural exposures may have produced these weak statistical associations. Furthermore, a pooled analysis of three of the case-control studies and the combined analysis of two retrospective follow-up studies did not demonstrate the types of dose-response or induction time patterns that would be expected if triazines were causal factors. The epidemiologic data pertaining to Hodgkin's disease, leukemia, multiple myeloma, soft tissue sarcoma, colon cancer, and ovarian cancer were inadequate for determining whether associations with atrazine or triazines exist in humans. For each of these cancers, only one or two studies evaluating the relationship were available, and the results of the studies typically were imprecise.
Insights
Epidemiologic studies on triazine herbicides, including atrazine, found weak associations with non-Hodgkin
Area of Science:
- Environmental Health
- Toxicology
- Epidemiology
Background:
- Triazine herbicides, particularly atrazine, are widely used globally.
- Concerns exist regarding their potential human carcinogenic effects.
Purpose of the Study:
- To evaluate the epidemiologic evidence on the carcinogenic potential of triazine herbicides in humans.
- To assess the association between triazine exposure and specific cancer types.
Main Methods:
- Review and analysis of existing epidemiologic studies.
- Focus on non-Hodgkin's lymphoma, Hodgkin's disease, leukemia, multiple myeloma, soft tissue sarcoma, colon, and ovarian cancers.
- Assessment of study limitations including exposure measurement and subject selection.
Main Results:
- Four case-control studies on triazines and non-Hodgkin's lymphoma showed weak odds ratios (1.2-2.5), potentially due to chance or confounding.
- Pooled and follow-up analyses did not reveal expected dose-response or induction time patterns for triazines as causal factors.
- Epidemiologic data for other assessed cancers were insufficient to establish any association with triazines or atrazine.
Conclusions:
- Current epidemiologic evidence does not strongly support a causal link between triazine herbicides and human cancers, particularly non-Hodgkin's lymphoma.
- Methodological limitations in existing studies hinder definitive conclusions.
- Further research with robust exposure assessment is needed for other cancer types.
Related Concept Videos
Cancer Prevention
Some...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Types of Toxins
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
Mutagenicity and Carcinogenicity
Toxicity Testing in Animals
Hazard Ratio
For example, in a clinical trial evaluating a...

